Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with focus on central nervous system disorders, including Parkinson’s disease, and endocrine disorders. This segment also provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson’s disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid for the treatment of hypothyroidism; and IPX203, a pipeline product for Parkinson’s disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.
Soaring Performance | Amneal Pharmaceuticals exceeds expectations across all segments, leading to a significant upward revision of revenue guidance and analyst optimism |
Product Pipeline | Explore Amneal's expanding portfolio, including the launch of CREXONT and upcoming IPX203, driving revenue growth and market interest |
Strategic Expansion | Delve into Amneal's foray into injectables and biosimilars, positioning the company for long-term growth in high-potential pharmaceutical segments |
Market Outlook | Analysts set price targets ranging from $8 to $10, reflecting confidence in Amneal's growth trajectory amid competitive challenges and regulatory landscapes |
Metrics to compare | AMRX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipAMRXPeersSector | |
---|---|---|---|---|
P/E Ratio | −14.7x | −3.6x | −0.6x | |
PEG Ratio | 0.00 | 0.03 | 0.00 | |
Price/Book | −28.9x | 1.2x | 2.6x | |
Price / LTM Sales | 1.0x | 1.2x | 3.2x | |
Upside (Analyst Target) | 8.8% | 1.7% | 44.1% | |
Fair Value Upside | Unlock | 9.4% | 6.2% | Unlock |